Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMB920Z)

Drug Name
Ceritinib Drug Info
Synonyms
ceritinib; LDK378; 1032900-25-6; ZYKADIA; NVP-LDK378-NX; LDK-378; UNII-K418KG2GET; LDK378(Ceritinib); LDK 378; Eritinib (LDK378); 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; K418KG2GET; CHEMBL2403108; CHEBI:78432; AK174337; ceritinib; C28H36ClN5O3S; 5-Chloro-N2-[2-isopropoxy-5-Methyl-4-(4-piperidyl)phenyl]-N4-(2-isopropylsulfonylphenyl)pyriMidine-2,4-diaMine; 5-Chloro-N2-(5-methyl-4-(piperidin-4-yl)-2-(propan-2-yloxy)phenyl)-N4-(2-(propane-2-sulfonyl)phenyl)pyrim
Indication
Disease Entry ICD 11 Status REF
Non-small-cell lung cancer 2C25.Y Approved [1]
Cross-matching ID
PubChem CID
57379345
ChEBI ID
CHEMBL78432
CAS Number
CAS 1032900-25-6
TTD Drug ID
DMB920Z
VARIDT Drug ID
DR00228
ACDINA Drug ID
D00115

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DTP
DOT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting ALK tyrosine kinase receptor (ALK)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Crizotinib DM4F29C Non-small-cell lung cancer 2C25.Y Approved [4]
Lorlatinib DMICDLV Non-small-cell lung cancer 2C25.Y Approved [5]
Entrectinib DMMPTLH Non-small-cell lung cancer 2C25 Approved [6]
Brigatinib DM7W94S Anaplastic large cell lymphoma 2A90.A Approved [7]
Repotrectinib DM9FB2T Non-small-cell lung cancer 2C25 Approved [8]
Alectinib DMP1I6Y Lung cancer 2C25.0 Approved [9]
Ensartinib DMIKDCQ Non-small-cell lung cancer 2C25.Y Phase 3 [8]
PF-06463922 DMKM7EW Non-small-cell lung cancer 2C25.Y Phase 2 [10]
AP26113 DMYBQEF Solid tumour/cancer 2A00-2F9Z Phase 2 [11]
TSR-011 DMFOR9Y Non-small-cell lung cancer 2C25.Y Phase 1/2 [12]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Transported By P-glycoprotein 1 (ABCB1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Amoxicillin DMUYNEI Acute otitis media AB00 Approved [13]
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [14]
Methotrexate DM2TEOL Anterior urethra cancer Approved [15]
Folic Acid DMEMBJC Colorectal carcinoma Approved [16]
Fluorouracil DMUM7HZ Adenocarcinoma 2D40 Approved [15]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [15]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [17]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [15]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [18]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [19]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Tyrosine-protein kinase JAK3 (JAK3)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Methotrexate DM2TEOL Anterior urethra cancer Approved [20]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [21]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [22]
Zoledronate DMIXC7G Adenocarcinoma 2D40 Approved [23]
Niclosamide DMJAGXQ Cestodes infection 1F70-1F76 Approved [24]
Diethylstilbestrol DMN3UXQ Gonorrheal vaginitis GA02 Approved [25]
Decitabine DMQL8XJ Acute myelogenous leukaemia 2A41 Approved [21]
Menadione DMSJDTY Vitamin K deficiency 5B59 Approved [26]
Arsenic DMTL2Y1 N. A. N. A. Approved [27]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [28]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Cytochrome c (CYCS)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [29]
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [30]
Gefitinib DM15F0X Colon adenocarcinoma Approved [31]
Leuprorelin acetate DM15HAT Prostate cancer 2C82.0 Approved [32]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [33]
Nitric Oxide DM1RBYG Hypertension BA00-BA04 Approved [34]
Methotrexate DM2TEOL Anterior urethra cancer Approved [20]
Quercetin DM3NC4M Obesity 5B81 Approved [35]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [36]
Pefloxacin DM49IGF Gonococcal urethritis 1A70.0Y Approved [37]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Transcription factor p65 (RELA)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [29]
Beta-carotene DM0RXBT Vitamin deficiency 5B55-5B71 Approved [38]
Selenium DM25CGV N. A. N. A. Approved [39]
Sulindac DM2QHZU Acute myelogenous leukaemia 2A41 Approved [40]
Simvastatin DM30SGU Arteriosclerosis BD40 Approved [41]
Deoxycholic acid DM3GYAL Subcutaneous fat disorder EF02 Approved [42]
Quercetin DM3NC4M Obesity 5B81 Approved [35]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [43]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [44]
Glucosamine DM4ZLFD Osteoarthritis FA00-FA05 Approved [45]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By TNF receptor-associated factor 2 (TRAF2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Simvastatin DM30SGU Arteriosclerosis BD40 Approved [46]
Quercetin DM3NC4M Obesity 5B81 Approved [47]
obeticholic acid DM3Q1SM Primary biliary cholangitis DB96.1 Approved [48]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [49]
Ivermectin DMDBX5F Intestinal strongyloidiasis due to nematode parasite 1F6B Approved [50]
Menthol DMG2KW7 Back pain ME84.Z Approved [51]
Zoledronate DMIXC7G Adenocarcinoma 2D40 Approved [52]
Cupric Sulfate DMP0NFQ Fungal infection 1F29-1F2F Approved [53]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [54]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [28]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Phosphatidylinositol 3-kinase catalytic subunit type 3 (PIK3C3)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Methotrexate DM2TEOL Anterior urethra cancer Approved [55]
Quercetin DM3NC4M Obesity 5B81 Approved [56]
Nefazodone DM4ZS8M Major depressive disorder 6A70.3 Approved [57]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [58]
Hydroquinone DM6AVR4 Melasma ED60.1 Approved [59]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [60]
Ivermectin DMDBX5F Intestinal strongyloidiasis due to nematode parasite 1F6B Approved [50]
Cholecalciferol DMGU74E Adult acute monocytic leukemia Approved [61]
Temozolomide DMKECZD Adenocarcinoma 2D40 Approved [62]
DTI-015 DMXZRW0 Brain cancer 2A00 Approved [62]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
ALK tyrosine kinase receptor (ALK) TTPMQSO ALK_HUMAN Modulator [1]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [2]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Cytochrome c (CYCS) OTBFALJD CYC_HUMAN Protein Interaction/Cellular Processes [3]
Phosphatidylinositol 3-kinase catalytic subunit type 3 (PIK3C3) OTLUM9L7 PK3C3_HUMAN Gene/Protein Processing [3]
TNF receptor-associated factor 2 (TRAF2) OT1MEZZN TRAF2_HUMAN Gene/Protein Processing [3]
Transcription factor p65 (RELA) OTUJP9CN TF65_HUMAN Protein Interaction/Cellular Processes [3]
Tyrosine-protein kinase JAK3 (JAK3) OTQ8QW2L JAK3_HUMAN Gene/Protein Processing [3]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7397).
2 P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer. EBioMedicine. 2015 Dec 12;3:54-66.
3 1-(4-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)-3-(2-(dimethylamino)ethyl)imidazolidin-2-one (ZX-42) inhibits cell proliferation and induces apoptosis via inhibiting ALK and its downstream pathways in Karpas299 cells. Toxicol Appl Pharmacol. 2022 Sep 1;450:116156. doi: 10.1016/j.taap.2022.116156. Epub 2022 Jul 6.
4 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
5 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
6 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
7 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
8 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
9 CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant. Cancer Cell. 2011 May 17;19(5):679-90.
10 PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models. Cancer Cell. 2015 Jul 13;28(1):70-81.
11 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
12 Treatment of ALK-positive non-small cell lung cancer. Arch Pathol Lab Med. 2012 Oct;136(10):1201-4.
13 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
14 MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
15 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
16 Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
17 Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
18 Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
19 Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
20 The contribution of methotrexate exposure and host factors on transcriptional variance in human liver. Toxicol Sci. 2007 Jun;97(2):582-94.
21 [Effect of arsenic trioxide and 5-aza-2'-deoxycytidine on SHP-1, JAK3, TYK2 gene expression in K562 cells]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2014 Apr;22(2):323-8. doi: 10.7534/j.issn.1009-2137.2014.02.011.
22 A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015 Sep;89(9):1599-618.
23 The proapoptotic effect of zoledronic acid is independent of either the bone microenvironment or the intrinsic resistance to bortezomib of myeloma cells and is enhanced by the combination with arsenic trioxide. Exp Hematol. 2011 Jan;39(1):55-65.
24 Mitochondrial Uncoupling Induces Epigenome Remodeling and Promotes Differentiation in Neuroblastoma. Cancer Res. 2023 Jan 18;83(2):181-194. doi: 10.1158/0008-5472.CAN-22-1029.
25 Analysis of gene expression induced by diethylstilbestrol (DES) in human primitive Mullerian duct cells using microarray. Cancer Lett. 2005 Apr 8;220(2):197-210.
26 Tyrosine phosphorylation of HuR by JAK3 triggers dissociation and degradation of HuR target mRNAs. Nucleic Acids Res. 2014 Jan;42(2):1196-208. doi: 10.1093/nar/gkt903. Epub 2013 Oct 7.
27 Prenatal arsenic exposure and the epigenome: identifying sites of 5-methylcytosine alterations that predict functional changes in gene expression in newborn cord blood and subsequent birth outcomes. Toxicol Sci. 2015 Jan;143(1):97-106. doi: 10.1093/toxsci/kfu210. Epub 2014 Oct 10.
28 Predictive toxicology using systemic biology and liver microfluidic "on chip" approaches: application to acetaminophen injury. Toxicol Appl Pharmacol. 2012 Mar 15;259(3):270-80.
29 Cannabidiol Modulates the Immunophenotype and Inhibits the Activation of the Inflammasome in Human Gingival Mesenchymal Stem Cells. Front Physiol. 2016 Nov 24;7:559. doi: 10.3389/fphys.2016.00559. eCollection 2016.
30 Regulation of ERRalpha gene expression by estrogen receptor agonists and antagonists in SKBR3 breast cancer cells: differential molecular mechanisms mediated by g protein-coupled receptor GPR30/GPER-1. Mol Endocrinol. 2010 May;24(5):969-80. doi: 10.1210/me.2009-0148. Epub 2010 Mar 8.
31 Evidence of securin-mediated resistance to gefitinib-induced apoptosis in human cancer cells. Chem Biol Interact. 2013 Apr 25;203(2):412-22. doi: 10.1016/j.cbi.2013.03.011. Epub 2013 Mar 22.
32 Effects of gonadotrophin-releasing hormone agonists on apoptosis of granulosa cells. Ann N Y Acad Sci. 2005 May;1042:531-7. doi: 10.1196/annals.1338.065.
33 K-RAS transformation in prostate epithelial cell overcomes H2O2-induced apoptosis via upregulation of gamma-glutamyltransferase-2. Toxicol In Vitro. 2012 Apr;26(3):429-34. doi: 10.1016/j.tiv.2012.01.013. Epub 2012 Jan 17.
34 Nitric oxide inhibits execution of apoptosis at two distinct ATP-dependent steps upstream and downstream of mitochondrial cytochrome c release. Biochem Biophys Res Commun. 1999 Apr 29;258(1):215-21. doi: 10.1006/bbrc.1999.0491.
35 Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
36 Troglitazone induces cytotoxicity in part by promoting the degradation of peroxisome proliferator-activated receptor co-activator-1 protein. Br J Pharmacol. 2010 Oct;161(4):771-81. doi: 10.1111/j.1476-5381.2010.00900.x.
37 Under ambient UVA exposure, pefloxacin exhibits both immunomodulatory and genotoxic effects via multiple mechanisms. J Photochem Photobiol B. 2018 Jan;178:593-605. doi: 10.1016/j.jphotobiol.2017.12.014. Epub 2017 Dec 15.
38 -Carotene Induces Apoptosis in Human Esophageal Squamous Cell Carcinoma Cell Lines via the Cav-1/AKT/NF-B Signaling Pathway. J Biochem Mol Toxicol. 2016 Mar;30(3):148-57. doi: 10.1002/jbt.21773. Epub 2016 Jan 6.
39 Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
40 Differential gene expression of sulindac-treated human breast epithelial cells. Int J Oncol. 2005 Dec;27(6):1727-36.
41 Suppression of RAGE as a basis of simvastatin-dependent plaque stabilization in type 2 diabetes. Arterioscler Thromb Vasc Biol. 2006 Dec;26(12):2716-23.
42 Prevention of deoxycholate-induced gastric apoptosis by aspirin: roles of NF-kappaB and PKC signaling. J Surg Res. 2008 Mar;145(1):66-73. doi: 10.1016/j.jss.2007.04.039. Epub 2007 Jul 20.
43 Peroxisome proliferator-activated receptor-gamma agonists inhibit respiratory syncytial virus-induced expression of intercellular adhesion molecule-1 in human lung epithelial cells. Immunology. 2007 May;121(1):71-81. doi: 10.1111/j.1365-2567.2006.02539.x.
44 Differential modulation of PI3-kinase/Akt pathway during all-trans retinoic acid- and Am80-induced HL-60 cell differentiation revealed by DNA microarray analysis. Biochem Pharmacol. 2004 Dec 1;68(11):2177-86.
45 Glucosamine regulation of LPS-mediated inflammation in human bronchial epithelial cells. Eur J Pharmacol. 2010 Jun 10;635(1-3):219-26. doi: 10.1016/j.ejphar.2010.02.044. Epub 2010 Mar 20.
46 Simvastatin potentiates TNF-alpha-induced apoptosis through the down-regulation of NF-kappaB-dependent antiapoptotic gene products: role of IkappaBalpha kinase and TGF-beta-activated kinase-1. J Immunol. 2007 Feb 15;178(4):2507-16. doi: 10.4049/jimmunol.178.4.2507.
47 Quercetin potentiates apoptosis by inhibiting nuclear factor-kappaB signaling in H460 lung cancer cells. Biol Pharm Bull. 2013;36(6):944-51. doi: 10.1248/bpb.b12-01004.
48 Pharmacotoxicology of clinically-relevant concentrations of obeticholic acid in an organotypic human hepatocyte system. Toxicol In Vitro. 2017 Mar;39:93-103.
49 Arsenic trioxide induces different gene expression profiles of genes related to growth and apoptosis in glioma cells dependent on the p53 status. Mol Biol Rep. 2008 Sep;35(3):421-9.
50 Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
51 Repurposing L-menthol for systems medicine and cancer therapeutics? L-menthol induces apoptosis through caspase 10 and by suppressing HSP90. OMICS. 2016 Jan;20(1):53-64.
52 Effect of zoledronic acid on oral fibroblasts and epithelial cells: a potential mechanism of bisphosphonate-associated osteonecrosis. Br J Haematol. 2009 Mar;144(5):667-76. doi: 10.1111/j.1365-2141.2008.07504.x. Epub 2008 Nov 20.
53 Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
54 Activation of AIFM2 enhances apoptosis of human lung cancer cells undergoing toxicological stress. Toxicol Lett. 2016 Sep 6;258:227-236.
55 Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium. Arthritis Rheumatol. 2014 Jan;66(1):15-23.
56 Multitarget effects of quercetin in leukemia. Cancer Prev Res (Phila). 2014 Dec;7(12):1240-50. doi: 10.1158/1940-6207.CAPR-13-0383. Epub 2014 Oct 7.
57 Robustness testing and optimization of an adverse outcome pathway on cholestatic liver injury. Arch Toxicol. 2020 Apr;94(4):1151-1172. doi: 10.1007/s00204-020-02691-9. Epub 2020 Mar 10.
58 Arsenic trioxide reduces the expression of E2F1, cyclin E, and phosphorylation of PI3K signaling molecules in acute leukemia cells. Environ Toxicol. 2021 Sep;36(9):1785-1792. doi: 10.1002/tox.23299. Epub 2021 May 27.
59 Keratinocyte-derived IL-36gama plays a role in hydroquinone-induced chemical leukoderma through inhibition of melanogenesis in human epidermal melanocytes. Arch Toxicol. 2019 Aug;93(8):2307-2320.
60 Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
61 Vitamin D3 induces autophagy of human myeloid leukemia cells. J Biol Chem. 2008 Sep 12;283(37):25596-25605. doi: 10.1074/jbc.M801716200. Epub 2008 Jul 15.
62 Tumor necrosis factor-alpha-induced protein 3 as a putative regulator of nuclear factor-kappaB-mediated resistance to O6-alkylating agents in human glioblastomas. J Clin Oncol. 2006 Jan 10;24(2):274-87. doi: 10.1200/JCO.2005.02.9405. Epub 2005 Dec 19.